BioCentury
ARTICLE | Clinical News

Parsatuzumab: Development discontinued

October 21, 2013 7:00 AM UTC

Roche disclosed in its 3Q13 update that it discontinued development of parsatuzumab after the compound as first-line treatment of metastatic non-small cell lung cancer (NSCLC) missed the primary endpo...